Ultragenyx Pharmaceutical Inc.(RARE)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,358 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
RARE Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Ultragenyx Pharmaceutical Inc. (RARE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RARE at 34.2/100 on a 32-signal composite quality model, placing it at rank #2,358 of 2,962 stocks — the bottom half of the AI-ranked universe. RARE scores in the top quartile across institutional flow (86.8), revenue growth (84.0). Areas of concern include balance sheet strength (4.2) and free cash flow (7.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Ultragenyx Pharmaceutical Inc. reports quarterly revenue of $214.0M, net income of $-92.0M, free cash flow of $-98.0M. Top institutional holders of RARE by reported 13-F value include BlackRock, RTW INVESTMENTS, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. RARE trades on the Nasdaq exchange and files with the SEC under CIK 1515673. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RARE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ultragenyx Pharmaceutical Inc. directly from SEC EDGAR. Ultragenyx Pharmaceutical Inc.'s 13F Pro composite quality score has ranged between 19 and 37 since 2021, currently 34.2 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$214.0M
Net Income
Q2 2026
$-92.0M
Free Cash Flow
Q2 2026
$-98.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+20.2% YoYNet Income
-1.1% YoYOperating Income
+0.2% YoYEPS (Diluted)
+7.3% YoYTotal Assets
+1.9% YoYOp. Cash Flow
-12.6% YoYFree Cash Flow
-12.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $673.0M +20.2% | $560.0M +29.0% | $434.0M +19.5% | $363.3M +3.4% | $351.4M +29.7% | $271.0M |
| Net Income | $-575.0M -1.1% | $-569.0M +6.3% | $-607.0M +14.2% | $-707.4M -55.8% | $-454.0M -143.4% | $-186.6M |
| Operating Income | $-535.0M +0.2% | $-536.0M +5.8% | $-569.0M +12.3% | $-648.9M -70.0% | $-381.7M -15.6% | $-330.1M |
| EPS (Diluted) | $-5.83 +7.3% | $-6.29 +23.8% | $-8.25 +18.5% | $-10.12 -51.0% | $-6.70 -118.2% | $-3.07 |
| Total Assets | $1.53B +1.9% | $1.50B +0.8% | $1.49B -3.5% | $1.55B +1.5% | $1.52B -13.5% | $1.76B |
| Operating Cash Flow | $-466.0M -12.6% | $-414.0M +12.8% | $-475.0M -24.8% | $-380.5M -12.3% | $-338.7M -156.2% | $-132.2M |
| Free Cash Flow | $-472.0M -12.1% | $-421.0M +18.9% | $-519.0M -4.5% | $-496.6M -20.6% | $-411.8M -133.8% | $-176.1M |
Get alerted when RARE's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Ultragenyx Pharmaceutical Inc. including:
Top Institutional Holders of RARE
BlackRock, Inc.
$355.7M10,654,276 shRTW INVESTMENTS, LP
$260.3M7,796,895 shVANGUARD PORTFOLIO MANAGEMENT LLC
$226.7M6,790,135 shAQR CAPITAL MANAGEMENT LLC
$214.1M6,560,809 shSTATE STREET CORP
$205.6M6,158,766 shVANGUARD CAPITAL MANAGEMENT LLC
$143.5M4,296,491 shTWO SIGMA INVESTMENTS, LP
$120.9M3,621,200 shSANDS CAPITAL MANAGEMENT, LLC
$105.5M3,158,368 shJACOBS LEVY EQUITY MANAGEMENT, INC
$98.2M2,939,719 shFRONTIER CAPITAL MANAGEMENT CO LLC
$95.1M2,847,936 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $355.7M | 10,654,276 |
| RTW INVESTMENTS, LP | $260.3M | 7,796,895 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $226.7M | 6,790,135 |
| AQR CAPITAL MANAGEMENT LLC | $214.1M | 6,560,809 |
| STATE STREET CORP | $205.6M | 6,158,766 |
| VANGUARD CAPITAL MANAGEMENT LLC | $143.5M | 4,296,491 |
| TWO SIGMA INVESTMENTS, LP | $120.9M | 3,621,200 |
| SANDS CAPITAL MANAGEMENT, LLC | $105.5M | 3,158,368 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $98.2M | 2,939,719 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $95.1M | 2,847,936 |
Companies Similar to RARE
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
INSMED Inc
ARDELYX, INC.
Axsome Therapeutics, Inc.
BridgeBio Pharma, Inc.
RHYTHM PHARMACEUTICALS, INC.
SUPERNUS PHARMACEUTICALS, INC.
Syndax Pharmaceuticals Inc
AGIOS PHARMACEUTICALS, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put RARE on your watchlist
Track score changes the day Ultragenyx Pharmaceutical Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RARE a good stock to buy?
13F Pro's AI-powered analysis of Ultragenyx Pharmaceutical Inc. (RARE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RARE are available on the RARE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RARE is classified as a small company.
Which hedge funds own RARE?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RARE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Ultragenyx Pharmaceutical Inc.'s investment landscape.